儿童髓母细胞瘤预后相关因素的研究进展  

Pediatric medulloblastomaupdate on prognosis factors

作　　者：顾硕[1] 武志祥[1] 吴晔明[1] 

机构地区：[1]上海交通大学医学院附属新华医院儿外科,上海200092

出　　处：《中国医师杂志》2016年第6期953-957,共5页Journal of Chinese Physician

基　　金：上海申康医院发展中心基金资助项目（SHDC12012110）

摘　　要：髓母细胞瘤是一种常见的儿童颅内肿瘤，目前传统治疗已经无法进一步提高治疗效果。随着基因科技以及分子研究技术的飞速进步，近年来髓母细胞瘤的分子遗传学和临床预后因素的研究得到不断进展，准确判定预后以及通过分子靶向治疗提高患者的预后呈现出新的曙光。Medulloblastoma is the most common malignant tumor of childhood. Over the past decade, progress in improving survival using conventional therapies has stalled. As advances in the molecular and genetic profiling of pediatric medulloblastoma evolve, associations with prognosis and treatment are found and research is directed at molecular therapies. The vast amount of genomic and molecular data generated over the last years encourages optimism that improved new molecular targets will improve outcomes.

关 键 词：髓母细胞瘤 预后 综述 

分 类 号：R739.4[医药卫生—肿瘤]